1. Home
  2. NGNE vs DDD Comparison

NGNE vs DDD Comparison

Compare NGNE & DDD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$31.76

Market Cap

327.8M

Sector

Health Care

ML Signal

HOLD

Logo 3D Systems Corporation

DDD

3D Systems Corporation

HOLD

Current Price

$3.23

Market Cap

343.2M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
NGNE
DDD
Founded
2003
1986
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer peripheral equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
327.8M
343.2M
IPO Year
2014
2003

Fundamental Metrics

Financial Performance
Metric
NGNE
DDD
Price
$31.76
$3.23
Analyst Decision
Strong Buy
Buy
Analyst Count
7
2
Target Price
$63.57
$4.75
AVG Volume (30 Days)
151.5K
3.9M
Earning Date
05-08-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
0.93
109.79
EPS
N/A
N/A
Revenue
N/A
$386,902,000.00
Revenue This Year
N/A
$2.48
Revenue Next Year
N/A
$4.10
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.65
$1.48
52 Week High
$37.27
$3.80

Technical Indicators

Market Signals
Indicator
NGNE
DDD
Relative Strength Index (RSI) 64.15 77.17
Support Level $18.25 $1.86
Resistance Level $32.02 $3.47
Average True Range (ATR) 2.33 0.21
MACD 0.17 0.09
Stochastic Oscillator 68.50 91.84

Price Performance

Historical Comparison
NGNE
DDD

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About DDD 3D Systems Corporation

3D Systems Corp provide comprehensive 3D printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, and services, including maintenance, manufacturing and applications engineering. Its solutions support applications in two key industry verticals: Healthcare Solutions provide surgical planning, implants, instrumentation, and medical education solutions to help medical device manufacturers and healthcare providers accelerate, and ultimately, transform healthcare, and Industrial Solutions which includes aerospace, defense, transportation and general manufacturing. The company operates in the Americas, EMEA, and APAC regions.

Share on Social Networks: